Heidelberg Pharma AG

Share Issue/Capital Change • Jul 19, 2010

News Details

Ad-hoc | 19 July 2010 08:19

WILEX AG resolves rights issue using authorised capital

WILEX AG / Capital Increase

19.07.2010 08:19

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities
Trading Act)

• Not for distribution, publication or transmission
  in the USA, Canada, Japan and Australia -

WILEX AG resolves rights issue using authorised capital

Munich, Germany, 19 July 2010. The Executive Management Board of WILEX AG
(ISIN DE0006614720 / WL6 / Frankfurt stock exchange) today resolved, with
the approval of the Supervisory Board, to increase the Company's share
capital using authorised capital from EUR 15,957,965.00 by up to EUR
2,455,070.00 to up to EUR 18,413,035.00 by issuing up to 2,455,070 new
no-par value shares with a pro-rata interest in capital of EUR 1.00 each
and full entitlement to dividends effective 1 December 2009 in return for
cash contributions.

WestLB AG, Düsseldorf, will offer the new shares to shareholders at a 13:2
ratio by means of an indirect subscription right. Hence, shareholders will
be entitled to subscribe for 2 new shares for each 13 existing shares held.
One of the existing shareholders has undertaken to waive its subscription
rights with respect to ten shares in order to ensure an even subscription
ratio.

The subscription period will begin on 21 July 2010 and will end on 03
August 2010. The subscription price is fixed at EUR 4.10. There will be no
organised trading in subscription rights.

Any new shares not subscribed for as a result of the offer may be purchased
by shareholders only - also at the subscription price - as part of an
additional subscription for shares. Binding offers for such additional
subscriptions must be submitted within the subscription period.

The new shares are to be admitted to trading in the regulated market on
Frankfurt stock exchange and in the Prime Standard (regulated market
segment that imposes further post-admission obligations) on the Frankfurt
stock exchange without the publication of an offering prospectus. The new
WILEX shares are due to be included in the existing listing on the
Frankfurt stock exchange on 6 August 2010.

The main shareholders dievini Hopp BioTech holding GmbH & Co. KG, Walldorf,
Germany and UCB Pharma S.A., Brussels, Belgium, - whose current interest in
the voting capital of WILEX AG is 35.65% and 18.05% respectively- have
advised that they intend to exercise their subscription rights.

WILEX AG plans to use the gross proceeds of approx. EUR 10.0 million from
the rights issue to finance its ongoing clinical studies and further growth
as well as to enhance its equity.

For further details on the rights issue, please see the subscription offer
provisionally planned to be published in the electronic Federal Gazette on
20 July 2010 and on the website of WILEX AG (www.wilex.com).

Important notes
This ad hoc release does not constitute either an offer to sell or an
invitation to buy securities. In particular, this document does not
constitute an offer to sell securities or a solicitation of an offer to buy
securities in the United States of America. The shares of WILEX AG (the
'Shares') may not be offered or sold in the United States of America or to
or for the account or benefit of 'U.S. persons' (as defined in Regulation S
under the U.S. Securities Act of 1933, as amended (the 'Securities Act')),
unless they have been registered or are exempt from registration under the
Securities Act. The Shares have not been and will not be registered under
the Securities Act. There will be no public offer of Shares in the United
States of America.

Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich; Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com

This communication contains certain forward-looking statements, relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by
general discussion of strategy, plans or intentions of the Company. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments. Given these uncertainties, prospective investors
and partners are cautioned not to place undue reliance on such
forward-looking statements. We disclaim any obligation to update any such
forward-looking statements to reflect future events or developments.

19.07.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---